Cerulean Pharma Inc. (CERU) Appoints Vice President, Clinical Operations

Cerulean Pharma Inc. (Nasdaq: CERU), a leader in Dynamic Tumor Targeting™, today announced the appointment of Tiffany Crowell as Vice President, Clinical Operations.

"Tiffany comes to Cerulean with deep experience and demonstrated leadership in clinical development and operations that will be crucial in supporting our clinical development of CRLX101 and CRLX301," said Paul Friedman, MD, Executive Chairman of Cerulean.

Suggested Articles

Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.

The deal gives Sarepta exclusive licenses to four CNS targets plus an option to pay a further $42.5 million to add another four targets to the deal.

In this week's EuroBiotech Report, AstraZeneca plans 2020 lupus filing, Roche's SMA trial hits endpoint and Kiadis cuts staff in R&D pivot.